Key clinical point: Black patients with type 2 diabetes may not derive a cardiovascular risk benefit from SGLT2 inhibitors and GLP-1R agonists.
Major finding: A pooled meta-analysis of black patients with type 2 diabetes who were treated with medications in both drug classes found no statistically significant evidence of a reduction in cardiovascular outcomes, compared with placebo (RR, 0.97; 95% CI, 0.68-1.39; P = .88).
Study details: Meta-analysis of six cardiovascular safety trials.
Disclosures: The authors reported no relevant disclosures.
Mishriky B et al. ADA 2019, Abstract 242-OR.